Meredith Garolds
Family · Statesville, NCNPI 1215546254
Payments from drug & device makers
Across 513 payments — averaging $22.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Inspire Medical Systems, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$913
- Boehringer Ingelheim$727
- Mylan Specialty L.p.$707
- plus $5K from 38 others
What the payments were for
- Travel & lodging$8187%
- Food & beverage$10,57191%
- Education$2692%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$723
How this compares
$11,658 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 188 | $155,857 |
| TezspireTezepelumab-Ekko | 11 | $49,742 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $22,876 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $15,584 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $14,296 |
| Spiriva RespimatTiotropium Bromide | 23 | $13,865 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $11,769 |
| Arnuity ElliptaFluticasone Furoate | 22 | $9,002 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $8,780 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 223 | $5,439 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $5,092 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,251 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $1,882 |
| Montelukast Sodium | 104 | $729 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 13 | $655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,729 | $199,831273 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,248 | $81,39777 claims |
| Boehringer IngelheimSpiriva Respimat | $727 | $13,86523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Statesville
- Kimberly WoodsStatesville$62K
- Deborah DaywaltStatesville$13K
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.